Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human TIGIT Protein, N-His

Catalog #:   YHH72401 Specific References (71) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: Q495A1
Protein length: Met22-Pro141
Overview

Catalog No.

YHH72401

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Met22-Pro141

Predicted molecular weight

15.37 kDa

Nature

Recombinant

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

Q495A1

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

VSTM3, TIGIT, V-set and transmembrane domain-containing protein 3, VSIG9, V-set and immunoglobulin domain-containing protein 9, T-cell immunoreceptor with Ig and ITIM domains

Note

For research use only.

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human TIGIT protein
References

Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis., PMID:40214505

The effect of TIGIT and PD1 expression on T cell function and prognosis in adult patients with acute myeloid leukemia at diagnosis., PMID:40214805

Single cell transcriptome sequencing indicates the cellular heterogeneity of small intestine tissue in celiac disease., PMID:40216823

Memory-promoting function of miR-379-5p attenuates CD8+ T cell exhaustion by targeting immune checkpoints., PMID:40221151

Anti-TIGIT inhibitors plus PD-1 or PD-L1 inhibitors versus PD-1 or PD-L1 inhibitors for first-line treatment of advanced non-small cell lung cancer., PMID:40226904

CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma., PMID:40234092

Heterogeneity of γδ T-cell subsets and their clinical correlation in patients with AML., PMID:40236710

Ara-C suppresses H3 K27-altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity., PMID:40238864

Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications., PMID:40243372

Promising New Anti-TIGIT Agents: Stealthy Allies in Cancer Immunotherapy., PMID:40261799

Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells., PMID:40274631

LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy., PMID:40277786

UBASH3A and TIGIT genes expression levels in systemic sclerosis., PMID:40285746

SLAM receptors regulate immune checkpoints via SAP and EAT- 2 in rheumatoid arthritis: association with disease activity., PMID:40287562

An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer., PMID:40289088

T-cell immunoglobulin and ITIM domain as a target in combo anti-PD-(L)1 cancer therapy., PMID:40294684

Immuno-PET Imaging of a 68Ga-Labeled Single-Domain Antibody for Detecting Tumor TIGIT Expression., PMID:40298304

Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia., PMID:40313965

Tph cells are expanded in IgA vasculitis nephritis., PMID:40315784

GD2-CAR NK-92 cell activity against neuroblastoma cells is insusceptible to TIGIT knockout., PMID:40317320

Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma., PMID:40326845

The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer., PMID:40327600

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti-TIGIT Therapy in Microsatellite-Stable Colorectal Cancer., PMID:40344511

Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families., PMID:40356928

Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies., PMID:40358739

TIGIT blockade increases efficacy of PD-1 blockade combined with radiation therapy in triple-negative breast cancer model., PMID:40360046

New Therapeutic Targets TIGIT, LAG-3 and TIM-3 in the Treatment of Advanced, Non-Small-Cell Lung Cancer., PMID:40362333

Single-cell analysis reveals potential therapeutic markers of peripheral blood mononuclear cells from bladder cancer patients., PMID:40367012

ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer., PMID:40371640

TIGIT deficiency promotes autoreactive CD4+ T-cell responses through a metabolic‒epigenetic mechanism in autoimmune myositis., PMID:40374622

Altered CD27-related T cell subsets reflect immune imbalance in systemic lupus erythematosus., PMID:40381105

NECTIN4 regulates the cell surface expression of CD155 in non-small cell lung cancer cells and induces tumor resistance to PD-1 inhibitors., PMID:40392373

Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356

Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy., PMID:40415479

NKG2D triggering hampers DNAM-1-mediated signaling in human NK cells., PMID:40421025

Distinct immunity dynamics of natural killer cells in mild and moderate COVID-19 cases during the Omicron variant phase., PMID:40421029

Desmocollin-3 and Bladder Cancer., PMID:40422563

Investigation of TIGIT, PVRIG, CD112 and CD155 expression in early and late onset preeclampsia., PMID:40425968

Investigating the molecular mechanisms associated with ulcerative colitis through the application of single-cell combined spatial transcriptome sequencing., PMID:40433374

Correlation of serum Helios, CD226, TIGIT, and Foxp3 with tear film osmotic pressure and dry eye disease in patients with rheumatoid arthritis., PMID:40442984

Impact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9., PMID:40445384

TERT promoter methylation predicts overall survival, immune cell infiltration and response to immunotherapy in clear cell renal cell carcinoma., PMID:40448175

Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy., PMID:40457441

Impact of immune checkpoint TIGIT on the activation and function of natural killer cells in rheumatoid arthritis patients., PMID:40465407

TIM3 and TIGIT-expressing CD4 T cells are impacted by kidney transplantation and associated with risk of infection., PMID:40475763

Expression of PSMD14 in lung adenocarcinoma and its impact on immune cell infiltration and prognosis: a comprehensive analysis based on RNA and single-cell RNA sequencing., PMID:40475775

Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs., PMID:40487483

SGSM1 as a pan-cancer biomarker: multi-omics insights into immune regulation, prognostic value, and therapeutic implications., PMID:40500484

Blockade of colon cancer metastasis via single and double silencing of PCSK7/PCSK9: enhanced T cells cytotoxicity in mouse and human., PMID:40518289

TIGIT blockade improves anti-Mycobacterium tuberculosis immunity., PMID:40526725

Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. PMID: 24745333

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. PMID: 33188038

TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro. PMID: 32804915

Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. PMID: 28623459

Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer. PMID: 32716559

Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas. PMID: 33158916

Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies. PMID: 33277440

Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. PMID: 21199897

CTLA-4: a moving target in immunotherapy. PMID: 29118008

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. PMID: 31238970

TIGIT predominantly regulates the immune response via regulatory T cells. PMID: 26413872

Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy. PMID: 33298247

TIGIT limits immune pathology during viral infections. PMID: 32152316

A Novel d-Peptide Identified by Mirror-Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy. PMID: 32386245

Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8(+) T Cells. PMID: 30555485

TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir. PMID: 32432050

The TIGIT/CD226 axis regulates human T cell function. PMID: 22427644

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. PMID: 19011627

A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade. PMID: 32782142

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes. PMID: 32903786

Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. PMID: 29500245

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human TIGIT Protein, N-His [YHH72401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2026 AntibodySystem All Rights Reserved.            All Products are for Research Use Only